Demographics and clinical characteristics of patients with idiopathic inflammatory myopathy and COVID-19 (N=348)
| Characteristics | |
| Age, mean (SD), years | 53.0 (15.5) |
| Age group, n (%) | |
| <30 | 26 (7.5) |
| 30–49 | 108 (31.0) |
| 50–65 | 136 (39.1) |
| >65 | 78 (22.4) |
| Gender, n (%) | |
| Female | 223 (64.1) |
| Race/ethnicity, n (%)* | |
| White | 157 (55.3) |
| Black | 34 (12.0) |
| Latinx | 68 (23.9) |
| Other | 25 (8.8) |
| Missing data | 64 |
| Region, n (%) | |
| Europe | 162 (46.6) |
| North America | 123 (35.3) |
| South America | 43 (12.4) |
| Other‡ | 20 (5.7) |
| Pandemic calendar period, n (%) | |
| 17 March 2020 to 15 June 2020 | 129 (37.2) |
| 16 June 2020 to 30 September 2020 | 51 (14.7) |
| 1 October 2020 to 27 August 2021 | 167 (48.1) |
| Comorbidities, n (%) | |
| Hypertension | 125 (25.9) |
| Other cardiovascular disease | 46 (36.2) |
| Hypertension or other cardiovascular disease | 139 (40.1) |
| Diabetes | 59 (17.0) |
| Chronic renal disease | 16 (4.6) |
| Interstitial lung disease | 87 (25.0) |
| Other chronic lung disease | 26 (7.5) |
| Cancer | 24 (6.9) |
| Obesity | 76 (21.8) |
| Ever smoker | 84 (31.1) |
| Comorbid count†, n (%) | |
| None | 139 (39.9) |
| One | 101 (29.0) |
| Two or more | 108 (31.0) |
| Disease activity, n (%)* | |
| Remission | 91 (29.8) |
| Low disease activity | 124 (40.7) |
| Moderate disease activity | 62 (20.3) |
| High disease activity | 28 (9.2) |
| Missing data | 43 |
| csDMARDs, n (%) | |
| MTX | 87 (25.0) |
| LEF | 7 (2.0) |
| SSZ | 1 (0.3) |
| HCQ | 52 (14.9) |
| Immunosuppressants, n (%) | |
| AZA | 51 (14.7) |
| CSA | 10 (2.9) |
| MMF | 71 (20.4) |
| TAC | 5 (1.4) |
| CYC | 10 (2.9) |
| bDMARDs, n (%) | |
| RTX | 63 (18.1) |
| Abatacept | 5 (1.4) |
| Anti-IL1 | 2 (0.6) |
| Anti-IL17 | 1 (0.3) |
| Anti-TNF | 1 (0.3) |
| tsDMARDs | |
| Apremilast | 2 (0.6) |
| JAKi, n (%) | 4 (1.1) |
| IVIg, n (%) | 26 (7.5) |
| Glucocorticoids (prednisolone-equivalent dose) | |
| No glucocorticoids | 111 (36.4) |
| >0 to 7.5 mg/day | 84 (27.5) |
| >7.5 mg/day | 110 (36.1) |
| DMARD/immunosuppressant medication category, n (%) | |
| No DMARD/immunosuppressant | 70 (20.1) |
| csDMARD only (HCQ/MTX/SSZ/LEF monotherapy or combination therapy) | 81 (23.3) |
| AZA monotherapy | 32 (9.2) |
| MMF monotherapy | 43 (12.4) |
| AZA/MMF combination therapy (except combination with RTX or b/tsDMARDs) | 27 (7.8) |
| CSA/CYC/TAC monotherapy or combination therapy (except RTX/b/tsDMARDs) | 17 (4.9) |
| b/tsDMARD monotherapy or combination therapy (except RTX) | 15 (4.3) |
| RTX (monotherapy or combination therapy with any other drug) | 63 (18.1) |
*Missing data excluded from the denominator when calculating percentages.
†Comorbid count includes hypertension, other cardiovascular disease, diabetes, chronic renal disease, chronic lung disease, cancer and obesity (BMI≥30).
‡Other regions with available patient data included South America, Eastern Mediterranean, South-East Asia and Western Pacific.
AZA, azathioprine; bDMARD, biologic DMARD; BMI, body mass index; CSA, ciclosporin; csDMARD, conventional synthetic DMARD; CYC, cyclophosphamide; DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; IL, interleukin; IVIg, intravenous immunoglobulin; JAKi, Janus kinase inhibitors; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TAC, tacrolimus; TNF, tumour necrosis factor; tsDMARD, targeted synthetic DMARD.